Needham reiterated coverage on Selecta Biosciences with a new price target
$SELB
Biotechnology: Pharmaceutical Preparations
Health Care
Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously